LCBM Lifecore Biomedical (MM)

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Lifecore Biomedical, Inc.

(Name of Subject Company)

Lifecore Biomedical, Inc.

(Name of Persons Filing Statement)

Common Shares
(Title of Class of Securities)

532187101
(CUSIP Number of Class of Securities)

Dennis J. Allingham
Lifecore Biomedical, Inc.
3515 Lyman Boulevard
Chaska, Minnesota 55318
(952) 368-4300
(Name, address and telephone numbers of person authorized to receive notices
and communications on behalf of the persons filing statement)

Copies to:

Robert A. Rosenbaum
Dorsey & Whitney LLP
50 South Sixth Street, Suite 1500
Minneapolis, Minnesota 55402
(612) 340-2600

o		Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

     This Amendment No. 1 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended, the “ Statement ”) initially filed by Lifecore Biomedical, Inc. (the “ Company ”) with the Securities Exchange Commission (the “ SEC ”) on February 21, 2008, relating to the cash tender offer by SBT Acquisition Inc., a Minnesota corporation and wholly owned subsidiary of SBT Holdings Inc., a Delaware corporation, disclosed in a Tender Offer Statement on Schedule TO dated February 21, 2008, filed with the SEC, to purchase all of the outstanding shares of the Company’s common stock at a price of $17.00 per share, net to the seller in cash, without interest and less any required withholding taxes, if any, upon the terms and subject to the conditions set forth in the Offer to Purchase dated February 21, 2008 (the “ Offer to Purchase ”), and the related Letter of Transmittal. Copies of the Offer to Purchase and the Letter of Transmittal were filed as Exhibits (a)(1) and (a)(2) to the Statement, respectively, and are incorporated herein by reference. Except as otherwise indicated herein, the information set forth in the Statement remains unchanged.

     The information in the Statement is incorporated in this Amendment by reference, except that such information is hereby amended and supplemented to the extent specifically provided herein.

     On the date hereof, the Company is filing Amendment No. 1 to the Statement with the SEC for the purpose of filing a Memorandum from the Company to all Option Holders, dated February 26, 2008, as an exhibit to the Statement.

SIGNATURES

     After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 26, 2008

INDEX TO EXHIBITS

Exhibit No.
Exhibit (a)(1)*		Offer to Purchase dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO, filed by Parent and Purchaser with respect to the Company on February 21, 2008 (the “ Schedule TO ”))
Exhibit (a)(2)*		Letter of Transmittal dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO)
Exhibit (a)(3)*		Press Release issued by the Company dated January 15, 2008 (incorporated by reference to the Schedule 14D-9C of the Company filed on January 15, 2008) and Transcript of conference call by the Company on January 15, 2008 relating to the proposed acquisition of the Company by Parent (incorporated by reference to the Schedule 14D-9C of the Company filed on January 15, 2008)
Exhibit (a)(4)*		Press Release issued by the Company dated February 14, 2008 (incorporated by reference to the Schedule TO-C filed by the Company on February 14, 2008)
Exhibit (a)(5)*		Press Release issued by Parent and Purchaser dated January 15, 2008 (incorporated by reference to the Schedule TO-C filed by the Company on January 15, 2008)
Exhibit (a)(6)*		Summary Advertisement published in The New York Times dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(I) to the Schedule TO)
Exhibit (a)(7)*		Letter to Shareholders of the Company dated February 21, 2008
Exhibit (a)(8)*		Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(D) to the Schedule TO)
Exhibit (a)(9)*		Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(E) to the Schedule TO)
Exhibit (a)(10)*		Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(C) to the Schedule TO)
Exhibit (a)(11)		Memorandum from the Company to all Option Holders dated February 26, 2008 (filed herewith)

Lifecore Biomedical (MM) (NASDAQ:LCBM)
Historical Stock Chart
From Apr 2024 to May 2024

Lifecore Biomedical (MM) (NASDAQ:LCBM)
Historical Stock Chart
From May 2023 to May 2024